A Study of Safety and Effectiveness of Evicel Fibrin Sealant as an Adjunctive Hemostat in Pediatric Surgery

Author:

Kenny Simon1,Gabra Hany2,Hall Nigel J.3,Flageole Helene4,Illie Bogdan5,Barnett Ellie6,Kocharian Richard5,Sharif Khalid7

Affiliation:

1. Department of Paediatric Surgery, Alder Hey Children's Hospital, Liverpool, Merseyside, United Kingdom of Great Britain and Northern Ireland

2. Department of Children's Surgery, Great North Children's Hospital, Newcastle Upon Tyne, United Kingdom of Great Britain and Northern Ireland

3. Department of Neonatal and Paediatric Surgery, Southampton Children's Hospital, Southampton

4. United Kingdom of Great Britain and Northern Ireland

5. Department of Pediatric Surgery, McMaster Children's Hospital, Hamilton, Ontario, Canada

6. Department of Scientific Affairs, Ethicon Inc, Raritan, New Jersey, United States

7. Department of Scientific Affairs, Ethicon UK, Livingston, United Kingdom of Great Britain and Northern Ireland

Abstract

Abstract Introduction Data on the use of fibrin sealants to control intraoperative bleeding in children are scarce. Evicel Fibrin Sealant (Ethicon Inc., Raritan, New Jersey, United States) was found safe and effective in clinical trials of adults undergoing various surgery types. We evaluated the safety and efficacy of Evicel versus Surgicel Absorbable Hemostat (Ethicon Inc.) as adjunctive topical hemostats for mild/moderate raw-surface bleeding in pediatric surgery. Methods A phase III randomized clinical trial was designed as required by the European Medicines Agency's Evicel Pediatric Investigation Plan: 40 pediatric subjects undergoing abdominal, retroperitoneal, pelvic, or thoracic surgery were randomized to Evicel or Surgicel, to treat intraoperative mild-to-moderate bleeding. Descriptive analyses included time-to-hemostasis and rates of treatment success (4, 7, 10 minutes), intraoperative treatment failure, rebleeding, and thromboembolic events. Results Forty of 130 screened subjects aged 0.9 to 17 years were randomized 1:1 to Evicel or Surgicel. Surgeries were predominantly open abdominal procedures. The median bleeding area was 4.0 cm2 for Evicel and 1.0 cm2 for Surgicel. The median time-to-hemostasis was 4.0 minutes for both groups. The 4-, 7-, and 10-minute treatment success rates were 80.0% versus 65.0%, 100.0% versus 80.0%, and 95.0% versus 90.0%, whereas treatment failure rates were 5.0% versus 25.0%, for Evicel and Surgicel, respectively. No deaths or thrombotic events occurred. Re-bleeding occurred in 5.0% of Evicel and 10.0% of Surgicel subjects. Conclusions In accordance with adult clinical trials, this randomized study supports the safety and efficacy of Evicel for controlling mild-to-moderate surgical bleeding in a broad range of pediatric surgical procedures.

Publisher

Georg Thieme Verlag KG

Reference34 articles.

1. Health and economic outcomes associated with uncontrolled surgical bleeding: a retrospective analysis of the Premier Perspectives Database;M Corral;Clinicoecon Outcomes Res,2015

2. Impact of bleeding complications on length of stay and critical care utilization in cardiac surgery patients in England;N Al-Attar;J Cardiothorac Surg,2019

3. Incidence and costs of bleeding-related complications in French hospitals following surgery for various diagnoses;X Ye;BMC Health Serv Res,2013

4. A comprehensive review of topical hemostatic agents: the good, the bad, and the novel;A J Tompeck;J Trauma Acute Care Surg,2020

5. A systematic review on the use of topical hemostats in trauma and emergency surgery;O Chiara;BMC Surg,2018

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3